Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Misidentification of Fungus Delays Outbreak Response

    Misidentification of Fungus Delays Outbreak Response

    C. auris may elude commonly used diagnostics

    July 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Fungus from the Pharmacy: An Unusual Outbreak of Nosocomial Fungemia

    Another Outbreak of Acute Flaccid Myelitis Could Complicate COVID-19 Response

    Public Perceptions of and Behavioral Changes in Response to the H1N1 Flu Outbreak

    Related Products

    Fungus from the Pharmacy: An Unusual Outbreak of Nosocomial Fungemia | Single Article

    Public Perceptions of and Behavioral Changes in Response to the H1N1 Flu Outbreak | Single Article

    Infection preventionists should ensure their labs have the diagnostic capabilities to detect multidrug-resistant Candida auris, which often is misidentified as less pathogenic fungi.

    “One of the challenges of C. auris is misidentification — most of the identification methods that clinical labs use cannot identify it reliably,” says Snigdha Vallabhaneni, MD, MPH, a medical epidemiologist in the mycotic diseases branch at the Centers for Disease Control and Prevention (CDC).

    If misidentification is suspected, clinicians can seek confirmation from state labs and the CDC’s nationwide Antibiotic Resistance Lab Network. “We know that this can be misidentified, but all you need is confirmation with appropriate identification methods.”

    The ability of the multidrug-resistant fungus to elude detection and continue spreading in the healthcare environment was dramatically underscored in a report of outbreak investigations in Colombia.1

    According to the CDC, the response to hospital outbreaks in Colombia in 2016 was hindered by misidentification of the pathogen.

    An unusual 75 isolates of Candida haemulonii — a yeast that rarely causes invasive infections — were reported in ICU patients by health officials.

    Looking at 45 of the isolates, the CDC and co-investigators determined, via matrix-assisted laser desorption ionization time-of-flight mass spectrometry, that all of them were C. auris.

    “Clinical laboratories should be aware that automated laboratory systems might incorrectly identify C. auris, particularly as C. haemulonii, although the species reported depends on the system,” the CDC advises.

    “C. auris can be misidentified as a number of different organisms when using traditional phenotypic methods for yeast identification such as VITEK 2 YST, API 20C, BD Phoenix yeast identification system, and MicroScan,” the CDC warns.1

    The type of misidentified organism varies somewhat by the diagnostic system used. The CDC lists these diagnostics systems and the Candida organisms most commonly misidentified:

    • Vitek 2 YST: C. haemulonii, C. duobushaemulonii;
    • API 20C: Rhodotorula glutinis (characteristic red color not present), C. sake;
    • BD Phoenix: C. haemulonii, C. catenulata;
    • MicroScan: C. famata, C. guilliermondii, C. lusitaniae, C. parapsilosis;
    • RapID Yeast Plus: C. parapsilosis.

    “As C. auris continues to gain recognition, updated versions of other yeast identification platforms may be able to identify [it],” the CDC advises.

    “Please consult the instrument manufacturer for more information. When in doubt, please forward suspected C. auris specimens to CDC or state or regional public health laboratories for further characterization.”

    “All confirmed isolates of C. auris should be reported to local and state public health officials and to CDC at candidaauris@cdc.gov,” the CDC says.

    If C. auris is confirmed in a healthcare facility, the CDC recommends conducting a lab look-back study to see if prior cases had been missed.

    “Review past microbiology records — as far back as 2015, if possible — to identify cases of confirmed or suspected C. auris,” the CDC advises.2

    REFERENCES

    1. Escandón P, Cáceres CH, Espinosa-Bode A, et al. CDC. Notes from the Field: Surveillance for Candida auris — Colombia, September 2016–May 2017. MMWR 2018;67(15);459–460.
    2. CDC: Recommendations for Infection Prevention and Control for Candida auris. Feb. 18, 2018. Accessed June 1, 2018, at:
      https://bit.ly/2Hapm7K.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Hospital Infection Control & Prevention

    View PDF
    Hospital Infection Control & Prevention (Vol. 45, No. 7) - July 2018
    July 1, 2018

    Table Of Contents

    Emerging Fungus Hard to Detect, Treat, Remove

    Misidentification of Fungus Delays Outbreak Response

    CDC Hammering Out Healthcare Worker Infection Control Guidelines

    The Next Wave: Diagnostic Stewardship

    NICU MRSA Surveillance: Seek, Find, Then What?

    Seeking Vaccines for HAIs

    Post-endoscopy Infections in Outpatient Surgery

    Joint Commission Looking at High-level Disinfection

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing